Sanjivani Paranteral Ltd

Sanjivani Paranteral has announced its financial results for the quarter ending February 2025, showing flat performance for the third quarter of FY24-25. However, net sales for the half-year reached Rs 35.48 crore, reflecting a year-on-year growth of 22.51%, indicating positive operational trends.

Sanjivani Paranteral has recently seen a revision in its score, reflecting its strong market performance and impressive annual returns. The stock, which has been added to MarketsMOJO's list, continues to trade above key moving averages, indicating a robust upward trend despite some intraday fluctuations.

Sanjivani Paranteral has recently experienced a revision in its stock evaluation, reflecting its strong performance in the pharmaceuticals sector. The stock has consistently outperformed its peers, achieving a notable 52-week high and demonstrating significant growth over the past year. Additionally, it has been added to MarketsMOJO's list, underscoring its positive market momentum.

Sanjivani Paranteral has recently been added to MarketsMOJO's list following a revision in its score, reflecting its strong market performance. The stock has consistently outperformed its sector and demonstrated significant gains over the past week, indicating a robust upward trend in the pharmaceuticals industry.

Sanjivani Paranteral has recently been added to MarketsMOJO's list following a revision in its score, reflecting the company's impressive performance in the pharmaceuticals sector. The stock has achieved an all-time high and has consistently outperformed its sector, showcasing a strong upward trend in its trading metrics.

Sanjivani Paranteral has recently experienced a revision in its stock evaluation, reflecting its strong performance in the pharmaceuticals sector. The company has been added to MarketsMOJO's list, highlighting its impressive returns and positive market momentum, as it continues to outperform both its sector and broader market indices.

Sanjivani Paranteral has recently been added to MarketsMOJO's list following a revision in its score, reflecting its strong market performance. The stock has shown resilience, trading just below its 52-week high and outperforming its sector. With a notable annual gain, the company continues to attract investor interest.

Sanjivani Paranteral has reached a new 52-week high, reflecting its strong performance in the pharmaceuticals sector. However, the stock has seen a revision in its score, indicating a shift in evaluation. Despite this, it remains above key moving averages, showcasing a positive trend in its market position. The stock has also been added to MarketsMOJO's list, highlighting its potential amidst a backdrop of impressive annual growth.

Sanjivani Paranteral has reached an all-time high stock price, reflecting its strong market performance. Recent adjustments in its evaluation highlight the stock's consistent gains and robust position above key moving averages. Additionally, it has been added to MarketsMOJO's list, underscoring its impressive returns compared to the broader market.

Sanjivani Paranteral, a microcap pharmaceutical company, has reported positive financial results for the quarter ending September 2024. The company's net sales have shown a significant increase, leading to improved profitability. However, the company's operating cash flow has been declining, which could impact its long-term growth.

Sanjivani Paranteral, a microcap pharmaceutical company, has been downgraded to a 'Hold' by MarketsMOJO on September 11, 2024. Despite a healthy long-term growth rate, recent performance and expensive valuation have led to this decision. The stock has shown significant improvement but is currently trading at a premium compared to its historical valuations.

Sanjivani Paranteral Ltd, a microcap pharmaceutical company, has reached an all-time high stock price of Rs.360.6 on September 8th, 2024. According to MarketsMOJO, the stock call for Sanjivani Paranteral is 'Buy', indicating potential for growth in the pharmaceutical industry. The stock has outperformed the sector today and is currently trading higher than its moving averages, showing a positive trend. With a 1-year performance of 259.36%, Sanjivani Paranteral is a company to watch out for in the microcap pharmaceutical sector.

Sanjivani Paranteral Ltd, a microcap pharmaceutical company, has recently reached an all-time high stock price of Rs. 360.6 on September 7th, 2024. With a 'Buy' call from MarketsMOJO and outperforming the Sensex, the company has shown strong potential for growth and is a promising investment opportunity in the pharmaceutical industry.

Sanjivani Paranteral, a microcap pharmaceutical company, has received a 'Buy' rating from MarketsMOJO on September 6th, 2024. The company has consistently shown positive results in the last four quarters, with its highest net sales and PBDIT in the last quarter. Its stock has also shown significant improvement and generated impressive returns. Majority of shareholders are non-institutional, indicating strong belief in the company's potential. Sanjivani Paranteral has consistently outperformed BSE 500, showcasing its consistent returns. With all these positive factors, MarketsMOJO has upgraded its rating to 'Buy'.

Sanjivani Paranteral Ltd, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs. 358.9 on September 6th, 2024. The stock has consistently outperformed its sector and has shown a growth of 283.62% in the last year, showcasing its strong performance and potential for growth in the pharmaceutical industry. However, MarketsMOJO has given a 'Sell' call for the stock, highlighting the need for thorough research and consultation before making any investment decisions.

Sanjivani Paranteral Ltd, a microcap pharmaceutical company, has seen a significant surge in its stock price, reaching an all-time high of Rs.347 on September 6, 2024. Despite a 'Sell' rating from MarketsMOJO, the company's stock has outperformed the Sensex by 273.40% in the past year and is currently trading above all its moving averages.

Sanjivani Paranteral Ltd, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs. 344 on September 5th, 2024. The stock has consistently outperformed the sector and has shown a 12.19% increase in the last 5 days. With a strong performance and impressive 1-year growth of 252.77%, the company is a promising player in the pharmaceutical industry.

Sanjivani Paranteral Ltd, a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching an all-time high of Rs. 338.55 on September 5th, 2024. The stock has been on an upward trend for the past five days, outperforming the sector by 1.43%. It has also shown a remarkable 1-year performance of 263.22%, showcasing its potential for growth. However, MarketsMOJO has given a 'Sell' call for the stock, and investors should conduct their own research before making any investment decisions.

Sanjivani Paranteral, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs. 334 on September 3rd, 2024. Despite a 'Sell' recommendation from MarketsMOJO, the stock has outperformed the sector by 4.1% and has been on a consecutive gain for the past 3 days. The stock is also trading higher than its moving averages and has shown an impressive 1-year performance of 268.09%, making it an attractive option for investors.